Strasbourg: The European Union edged its critical medicines law toward the finish line this summer, as negotiators prepared the Critical Medicines Act for formal adoption in the autumn after the Council and Parliament struck a provisional deal in May 2026. The regulation aims to stop the recurring shortages that leave pharmacies short of everyday drugs.
The Act targets the supply of critical medicines such as antibiotics, insulin and common painkillers. It seeks to diversify supply chains, make it easier for governments to buy together, and rebuild manufacturing of both finished medicines and their active ingredients inside Europe.
Lawmakers want to cut the bloc’s heavy reliance on a handful of factories in Asia for essential compounds. Years of stock-outs, worsened during winter respiratory seasons, exposed how a single plant failure abroad can empty shelves across the continent.
Under the deal, the Commission would also weigh building health-security clauses into future free trade agreements, so that supply of critical medicines becomes part of Europe’s wider economic diplomacy.
Olivér Várhelyi, the Commissioner for Health and Animal Welfare, welcomed the agreement as a turning point for patients.
“No European should be told a life-saving medicine is out of stock,” Várhelyi said. “This law gives us the tools to make our own supply, buy it together and stand our ground when shortages hit.”
The Commission first proposed the Act in March 2025, and Parliament’s health committee shaped its position before the two institutions reached their provisional agreement on 12 May 2026. Both sides now complete legal and linguistic revision before a final vote.
Officials expect formal adoption in the fourth quarter of 2026. The text will then appear in the Official Journal, and the new rules will enter into force twenty days after publication, with application dates confirmed at that point.
The Act also builds new machinery for joint action. It lets governments pool orders through coordinated procurement, sets up mechanisms to steer investment toward strategic manufacturing sites, and gives the Commission a role in spotting looming shortages before they reach patients. Officials say the joint-buying tools mirror the approach the bloc took on vaccines during the pandemic.
Not everyone cheered. Some health groups warned that steering supply toward Europe could pull scarce medicines away from lower-income countries that depend on the same manufacturers, a concern raised sharply during the Parliament debate.
The measure forms part of a broader pharmaceutical overhaul that Brussels has pursued since 2023 to shore up supply security. Readers can review the Council statement and the Commission reaction for the agreed detail.
If the timetable holds, the critical medicines rules will move from political promise to binding law within months, giving governments a fresh toolkit before the next shortage season tests Europe’s pharmacies again.
